Literature DB >> 22580292

Human cells: new platform for recombinant therapeutic protein production.

Kamilla Swiech1, Virgínia Picanço-Castro, Dimas Tadeu Covas.   

Abstract

The demand for recombinant therapeutic proteins is significantly increasing. There is a constant need to improve the existing expression systems, and also developing novel approaches to face the therapeutic proteins demands. Human cell lines have emerged as a new and powerful alternative for the production of human therapeutic proteins because this expression system is expected to produce recombinant proteins with post translation modifications more similar to their natural counterpart and reduce the potential immunogenic reactions against nonhuman epitopes. Currently, little information about the cultivation of human cells for the production of biopharmaceuticals is available. These cells have shown efficient production in laboratory scale and represent an important tool for the pharmaceutical industry. This review presents the cell lines available for large-scale recombinant proteins production and evaluates critically the advantages of this expression system in comparison with other expression systems for recombinant therapeutic protein production.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22580292     DOI: 10.1016/j.pep.2012.04.023

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  30 in total

Review 1.  Photosynthetic biomanufacturing in green algae; production of recombinant proteins for industrial, nutritional, and medical uses.

Authors:  Beth A Rasala; Stephen P Mayfield
Journal:  Photosynth Res       Date:  2014-03-22       Impact factor: 3.573

2.  Variability among TSH Measurements Can Be Reduced by Combining a Glycoengineered Calibrator to Epitope-Defined Immunoassays.

Authors:  Sandrine Donadio-Andréi; Karim Chikh; Christine Heuclin; Elisabetta Kuczewski; Anne Charrié; Anne-Sophie Gauchez; Catherine Ronin
Journal:  Eur Thyroid J       Date:  2016-12-22

3.  Establishment and characterization of cell clones from the Papilio cell line RIRI-PaDe-3 by a high-efficiency clonal method.

Authors:  Zhi-Gang Liu; Wei-Feng Ding; Shi-Cong Xie; Na Sun; Xin Zhang; Xian Li; Ying Feng
Journal:  Cytotechnology       Date:  2018-04-09       Impact factor: 2.058

4.  Glycoengineering of Mammalian Expression Systems on a Cellular Level.

Authors:  Kelley M Heffner; Qiong Wang; Deniz Baycin Hizal; Özge Can; Michael J Betenbaugh
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

5.  A leader sequence capable of enhancing RNA expression and protein synthesis in mammalian cells.

Authors:  Brian P Wellensiek; Andrew C Larsen; Julia Flores; Bertram L Jacobs; John C Chaput
Journal:  Protein Sci       Date:  2013-09-04       Impact factor: 6.725

Review 6.  Humanizing glycosylation pathways in eukaryotic expression systems.

Authors:  Amjad Hayat Khan; Hadi Bayat; Masoumeh Rajabibazl; Suriana Sabri; Azam Rahimpour
Journal:  World J Microbiol Biotechnol       Date:  2016-11-11       Impact factor: 3.312

Review 7.  High-throughput cloning and expression library creation for functional proteomics.

Authors:  Fernanda Festa; Jason Steel; Xiaofang Bian; Joshua Labaer
Journal:  Proteomics       Date:  2013-04-05       Impact factor: 3.984

Review 8.  Better and faster: improvements and optimization for mammalian recombinant protein production.

Authors:  Steven C Almo; James D Love
Journal:  Curr Opin Struct Biol       Date:  2014-04-12       Impact factor: 6.809

Review 9.  The impact of the immune system on the safety and efficiency of enzyme replacement therapy in lysosomal storage disorders.

Authors:  A Broomfield; S A Jones; S M Hughes; B W Bigger
Journal:  J Inherit Metab Dis       Date:  2016-02-16       Impact factor: 4.982

Review 10.  Production of Therapeutic Enzymes by Lentivirus Transgenesis.

Authors:  María Celeste Rodríguez; Natalia Ceaglio; Sebastián Antuña; María Belén Tardivo; Marina Etcheverrigaray; Claudio Prieto
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.